Profile: Idenix Pharmaceuticals Inc (IDIX.OQ)
Idenix Pharmaceuticals, Inc. (Idenix), incorporated on May 30, 2002, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.
The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. During HCV replication, the viral polymerase, also called the NS5B polymerase, is the key enzyme that replicates the viral genetic information contained in the HCV viral genetic material, which is known as viral ribonucleic acid (RNA). NS5A is a multifunctional, nonstructural HCV protein that is important for the formation of viral replication complexes, the process of viral replication and virus assembly.
IDX184 is a liver-targeted nucleotide prodrug that enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate. The Company's lead drug candidate for the Company's NS5A inhibitor program is IDX719. Its drug candidate for its non-nucleoside polymerase inhibitor program was IDX375, a palm-binding polymerase inhibitor.
The Company developed a non-nucleoside reverse transcriptase inhibitor, or NNRTI, drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1 (HIV), and acquired immune deficiency syndrome (AIDS), for use in combination therapy. This agreement, which it refers to as the ViiV license agreement, was assigned to ViiV Healthcare Company (ViiV), which is an affiliate of GlaxoSmithKline.
In collaboration with Novartis, the Company developed Tyzeka/Sebivo. Tyzeka/Sebivo was developed through commercialization for the treatment of patients with HBV.
The Company's scientists have developed set of skills in compound generation, target selection, screening and pharmacology, preclinical development and lead optimization. The Company is utilizing these skills and capabilities in its discovery and development of antiviral drug candidates.
The Company competes with Abbott Laboratories, Achillion Pharmaceuticals, Inc., Biota Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Enanta Pharmaceuticals, Inc., F. Hoffman-LaRoche & Co., Gilead Sciences, Inc., GSK, Johnson & Johnson, Medivir, Merck & Co., Inc., Novartis, Presidio Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc, Isis Pharmaceuticals, Inc., Ribapharm, Inc., Genelabs Technologies, Inc. and Biota, Inc.
Idenix Pharmaceuticals Inc
320 BENT STREET
CAMBRIDGE MA 2141